{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:22:18Z","timestamp":1756902138034,"version":"3.44.0"},"reference-count":9,"publisher":"The Pediatric Pharmacy Association","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"abstract":"<jats:p>Lung damage caused by non-tuberculous mycobacteria (NTM) infections can be devastating to individuals that are predisposed to chronic respiratory colonization. Cystic fibrosis patients are at increased risk for diminished lung function and increased mortality from NTM pulmonary infections. Treatment regimens are often intense and prolonged. The case described in this report is of a 16-year-old male with cystic fibrosis infected with <jats:italic>Mycobacterium abscessus<\/jats:italic> who showed evidence of severe nodular pulmonary disease on chest computerized tomography. His intensive treatment phase was complicated by neutropenia and drug resistance, leading to the use of omadacycline. Because of rapid improvement clinically and on computed tomography, he was successfully treated with a modified, less intense continuation phase that included azithromycin, omadacycline, and inhaled amikacin. The patient also was switched from tezacaftor\/ivacaftor to elexacaftor\/tezacaftor\/ivacaftor during the course of NTM treatment.<\/jats:p>","DOI":"10.5863\/1551-6776-28.2.172","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T15:32:53Z","timestamp":1682523173000},"page":"172-176","source":"Crossref","is-referenced-by-count":3,"title":["Use of Omadacycline as a Component of Mycobacterium Abscessus Eradication in an Adolescent With Cystic Fibrosis"],"prefix":"10.5863","volume":"28","author":[{"given":"Mary Kate","family":"Tucker","sequence":"first","affiliation":[{"name":"The Children's Hospital at Saint Francis (MKT, LD, MC), Tulsa, OK"},{"name":"Warren Clinic Pediatric Pulmonology, Tulsa CF Center (MKT, LD, MC) Tulsa, OK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee","family":"Droemer","sequence":"additional","affiliation":[{"name":"The Children's Hospital at Saint Francis (MKT, LD, MC), Tulsa, OK"},{"name":"Warren Clinic Pediatric Pulmonology, Tulsa CF Center (MKT, LD, MC) Tulsa, OK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Condren","sequence":"additional","affiliation":[{"name":"The Children's Hospital at Saint Francis (MKT, LD, MC), Tulsa, OK"},{"name":"Warren Clinic Pediatric Pulmonology, Tulsa CF Center (MKT, LD, MC) Tulsa, OK"},{"name":"Department of Pediatrics (MC), The University of Oklahoma School of Community Medicine, Oklahoma City, OK"},{"name":"Children's Medical Center Dallas (MKT) Dallas, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","reference":[{"issue":"2","key":"i2331-348X-28-2-172-b1","series-title":"J Cyst Fibros","first-page":"117","article-title":"Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis","volume":"9","year":"2010","unstructured":"Esther\n              CR\n              Jr,\n            \n            \n              Esserman\n              DA\n            ,\n\t\t\t\t\t\tGilliganP,\n\t\t\t\t\t\n          .\n\t\t\t\t\tChronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis.\n\t\t\t\t\tJ Cyst Fibros.\n\t\t\t\t\t2010;9(2):117\u2013123."},{"issue":"6","key":"i2331-348X-28-2-172-b2","series-title":"Am J Resp Crit Care Med","first-page":"621","article-title":"Late diagnosis defines a unique population of long-term survivors of cystic fibrosis","volume":"171","year":"2015","unstructured":"Rodman\n              DM\n            ,\n\t\t\t\t\t\tPolisJM,\n\t\t\t\t\t\tHeltsheSL,\n\t\t\t\t\t\n          .\n\t\t\t\t\tLate diagnosis defines a unique population of long-term survivors of cystic fibrosis.\n\t\t\t\t\tAm J Resp Crit Care Med.\n\t\t\t\t\t2015;171(6):621\u2013626."},{"issue":"6","key":"i2331-348X-28-2-172-b3","series-title":"Am J Resp Crit Care Med","first-page":"828","article-title":"Nontuberculous mycobacteria, I: multicenter prevalence study in cystic fibrosis","volume":"167","year":"2003","unstructured":"Olivier\n              KN\n            ,\n\t\t\t\t\t\tWeberJ,\n\t\t\t\t\t\tWallaceRJJr,\n          .\n\t\t\t\t\tNontuberculous mycobacteria, I: multicenter prevalence study in cystic fibrosis.\n\t\t\t\t\tAm J Resp Crit Care Med.\n\t\t\t\t\t2003;167(6):828\u2013834."},{"issue":"suppl 1","key":"i2331-348X-28-2-172-b4","series-title":"Thorax","first-page":"i1","article-title":"US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis","volume":"71","year":"2016","unstructured":"Floto\n              RA\n            ,\n\t\t\t\t\t\tOlivierKN,\n\t\t\t\t\t\tSaimanL, ;\n\t\t\t\t\t\tUS Cystic Fibrosis Foundation and European Cystic Fibrosis Society.\n\t\t\t\t\t\n          US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis.\n\t\t\t\t\tThorax.\n\t\t\t\t\t2016;71(suppl 1):i1\u2013i22."},{"issue":"5","key":"i2331-348X-28-2-172-b5","series-title":"Clin Infect Dis,","first-page":"890","article-title":"Omadacycline: a novel tetracycline derivative with oral and intravenous formulations","volume":"69","year":"2019","unstructured":"Watkins\n              RR\n            ,\n\t\t\t\t\t\tDeresinskiS.\n          Omadacycline: a novel tetracycline derivative with oral and intravenous formulations.\n\t\t\t\t\tClin Infect Dis,2019;69(5):890\u2013896."},{"issue":"10","key":"i2331-348X-28-2-172-b6","series-title":"Open Forum Infect Dis","first-page":"ofaa415","article-title":"Omadacycline for the treatment of Mycobacterium abscessus disease: a case series","volume":"7","year":"2020","unstructured":"Pearson\n              JC\n            ,\n\t\t\t\t\t\tDionneB,\n\t\t\t\t\t\tRichtermanA,\n\t\t\t\t\t\n          .\n\t\t\t\t\tOmadacycline for the treatment of Mycobacterium abscessus disease: a case series.\n\t\t\t\t\tOpen Forum Infect Dis.\n\t\t\t\t\t2020;7(10):ofaa415."},{"issue":"2","key":"i2331-348X-28-2-172-b7","series-title":"Open Forum Infect Dis","first-page":"ofab002","article-title":"Preliminary, real-world, multicenter experience with omadacycline for Mycobacterium abscessus infections","volume":"8","year":"2021","unstructured":"Morrisette\n              T\n            ,\n\t\t\t\t\t\tAlosaimyS,\n\t\t\t\t\t\tPhilleyJV,\n\t\t\t\t\t\n          .\n\t\t\t\t\tPreliminary, real-world, multicenter experience with omadacycline for Mycobacterium abscessus infections.\n\t\t\t\t\tOpen Forum Infect Dis.\n\t\t\t\t\t2021;8(2):ofab002."},{"issue":"12","key":"i2331-348X-28-2-172-b8","series-title":"Pediatr Pulmonol","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1002\/ppul.25637","article-title":"Twelve years of progressive Mycobacterium abscessus lung disease in CF--response to Trikafta","volume":"56","year":"2021","unstructured":"Gur\n              M\n            ,\n\t\t\t\t\t\tBar-YosephR,\n\t\t\t\t\t\tToukanY,\n\t\t\t\t\t\n          .\n\t\t\t\t\tTwelve years of progressive Mycobacterium abscessus lung disease in CF--response to TrikaftaPediatr Pulmonol.\n\t\t\t\t\t2021;56(12):4048\u20134050.\n\t\t\t\t\tDoi:10.1002\/ppul.25637."},{"issue":"suppl 3","key":"i2331-348X-28-2-172-b9","series-title":"Pediatr Pulmonol","first-page":"S18","article-title":"Improving outcomes of infections in cystic fibrosis in the era of CFTR modulator therapy","volume":"54","year":"2019","unstructured":"Saiman\n              L.\n            \n          \n          Improving outcomes of infections in cystic fibrosis in the era of CFTR modulator therapy.\n\t\t\t\t\tPediatr Pulmonol.\n\t\t\t\t\t2019;54(suppl 3):S18\u2013S26."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/28\/2\/article-p172.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/28\/2\/172\/3213283\/i2331-348x-28-2-172.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/28\/2\/article-p172.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/28\/2\/article-p172.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:48:17Z","timestamp":1747356497000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/28\/2\/article-p172.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":9,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-28.2.172","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"type":"electronic","value":"2331-348X"},{"type":"print","value":"1551-6776"}],"subject":[],"published":{"date-parts":[[2023]]}}}